RECEIVED CENTRAL FAX CENTER

FEB 0 2 2006

Facsimile Transmittal Sheet

Date	2/2/06 Time 10:28AM		Pages Including This Title Page 10		
То	Examiner C.P. Bruenjes U.S. Patent & Trademark Office			From	Norman L. Sims
				Company	The Dow Chemical Company
Fax	(571) 273-8300 (central fax number)			Sender's Fax	248/391-6550
Phone	571/272-1498			Sender's Phone	248/391-6455
Appln. Serial No.	10/673,615			Dow Docket No.	61537B
Subject:	Response to Final Rejection				
Urgent	For Review	☐ Please Comment	☐ Please Reply	y Please Recyc	ela Please call to confirm receipt of this facsimile
Comment Please see th					
Dow Information Classification: ☑ DOW CONFIDENTIAL – Do not share without permission ☐					NFIDENTIAL – Do not share without permission _ – Do not share without permission

This message is intended for the use of the party to whom it is addressed. It may contain confidential business information. If you are not the intended recipient or an agent of the recipient, any use of this communication is prohibited. If you have received this communication in error, please notify the sender immediately by calling collect, then immediately destroy this message. Thank you.

Form No. 152-01653-1203XQRP

RECEIVED **CENTRAL FAX CENTER**

FEB 0 2 2006

RESPONSE UNDER 37 CFR 1.116 EXPEDITED PROCEDURE EXAMINING GROUP 1772

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No.

10/673.615

Confirmation No. 2556

Applicant (s)

Ravi Ramanathan et al. September 29, 2003

Filed TC/A.U.

1772

Examiner Title

C.P. Bruenjes **FUEL TANKS**

Docket No.

61537B

Customer No.

00109

CERTIFICATION OF FACSIMILE TRANSMISSION I HEREBY CERTIFY THAT THIS PAPER IS BEING FACSIMILE TRANSMITTED TO THE U.S. PATENT OFFICE ON THE DATE SHOWN BELOW

Mail Stop AF Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

RESPONSE TO FINAL REJECTION

Responsive to the Final Rejection dated December 5, 2005, Applicants respectfully request reconsideration of the Final Rejection in view of the remarks presented hereinafter and solicit early allowance of Claims 1-15, 21, 23-30 and 39.

Remarks/Arguments begin on page 2 of this paper.